GPC Biotech To Provide Update On Research And Development Programs At Jpmorgan 26th Annual Healthcare Conference In San Francisco

Martinsried, Germany, Jan 7, 2008 - (Hugin via ABN Newswire) - Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------



Martinsried/Munich (Germany) and Princeton, N.J., Monday, January 7, 2008 - GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that the Company will give a company update at the JPMorgan 26th Annual Healthcare Conference in San Francisco, CA. The Company will provide an update on its research and development pipeline. Additional information on satraplatin, including the SPARC trial and development plan for the compound, as well as updates on other programs, will be presented.

The presentation will be today, Monday, January 7, 2008, at 3:30 PM PST at the Westin St. Francis, San Francisco, CA. The presentation will be webcast live and will be accessible through the GPC Biotech Web site at www.gpc-biotech.com. A replay will also be available via the Web site.

About GPC Biotech GPC Biotech AG is a publicly traded biopharmaceutical company with a mission to discover, develop and commercialize new anticancer drugs. GPC Biotech's lead product candidate is satraplatin, an oral platinum compound. The Company has various anti-cancer programs in research and development that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

For further information, please contact:

GPC Biotech AG Martin Braendle Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 ir@gpc-biotech.com

In the U.S.: Laurie Doyle Director, Investor Relations & Corporate Communications Phone: 1-609-524-5884 usinvestors@gpc-biotech.co

--- End of Message ---

GPC Biotech AG Fraunhoferstr. 20 Martinsried

WKN: 585150; ISIN: DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX, TECH All Share; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Geregelter Markt in Frankfurter Wertpapierbörse;

Copyright © Hugin ASA 2008. All rights reserved.

GPC Biotech AG

http://www.gpc-biotech.com/

ISIN: DE0005851505

Stock Identifier: XFRA.GPC

US: NASDAQ: GPCB